{"entity":{"id":"zst-101","kind":"drug","name":"ZST-101","aka":[],"tldr":"ZST-101 is an experimental radioactive medicine from ZEeST Bio for hepatocellular carcinoma, the commonest primary liver cancer. It is in laboratory testing.","summary":"ZST-101 is the lead programme of ZEeST Bio, a radiotherapeutic built on a theranostic radiopharmaceutical platform for hepatocellular carcinoma, listed as preclinical on the company's pipeline. No clinical data exist.","status":"preclinical","asOf":"2026-11-04","links":[{"label":"ZEeST Bio: pipeline","url":"https://zeest.bio/"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["zeest-bio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"code":"ZST-101","modality":"Theranostic radiopharmaceutical","mechanism":"A radiopharmaceutical carried into liver tumours by a clinically validated hepatotropic uptake mechanism, designed for both imaging and therapy, as the developer describes.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/zst-101/","neighbours":{"company":[{"id":"zeest-bio","kind":"company","name":"ZEeST Bio","route":"/companies/zeest-bio/"}]}}